How to Buy Kiniksa Pharmaceuticals International Stock
Kiniksa Pharmaceuticals International PLC
Kiniksa Pharmaceuticals, Ltd. , a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
Kiniksa Pharmaceuticals International stock last closed at $41.14, down 0.99% from the previous day, and has increased 92.96% in one year. It has overperformed other stocks in the Biotechnology industry by 1.41 percentage points. Kiniksa Pharmaceuticals International stock is currently +130.86% from its 52-week low of $17.82, and -4.28% from its 52-week high of $42.98.
At the moment, there are 75.8M KNSA shares outstanding. The market value of KNSA is $3.12B. In the last 24 hours, 567,000 KNSA shares were traded.
How to Buy Kiniksa Pharmaceuticals International Stock
Not sure how to invest in Kiniksa Pharmaceuticals International stock? Here's how.
Choose where to buy Kiniksa Pharmaceuticals International stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you determine where to buy Kiniksa Pharmaceuticals International stock.
Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Deposit money your investment account: Select your payment method and add your details.
Evaluate Kiniksa Pharmaceuticals International stock: The Kiniksa Pharmaceuticals International ticker symbol is KNSA. Is Kiniksa Pharmaceuticals International stock a good investment? Should you buy shares of KNSA? How do KNSA's underlying business fundamentals look? Do top analysts think Kiniksa Pharmaceuticals International is a good buy? Why has KNSA's stock price moved recently? (Hint: Our stock analysis website can help you understand if KNSA is a good stock to buy).
Place your KNSA purchase: Decide if you will purchase KNSA shares at the current market price or use a limit order to buy KNSA shares at a given price.
Keep tabs on your KNSA investment: Create a watchlist to important notifications about your position in Kiniksa Pharmaceuticals International stock.
Step 1: Choose where to buy Kiniksa Pharmaceuticals International stock
You will need a brokerage account in order to access the NASDAQ market and buy KNSA stock.
A brokerage account allows you to buy and sell a number of investments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
Based on our research, eToro is the best stock brokerage. eToro gives you:
You can invest in stocks with 0% commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
Access to world markets: From Technology to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal information so you are able to invest in KNSA stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Kiniksa Pharmaceuticals International stock
After you have chosen the best place to buy Kiniksa Pharmaceuticals International stock, it's critical to analyze their stock prior to buying, so you can understand the risk as well as the opportunity.
Kiniksa Pharmaceuticals International shares quick numbers
KNSA Price
$41.14
1w %
2.67%
1y %
92.96%
5y %
140.02%
P/E
83.96x
P/B
5.82x
P/S
5.14x
PEG
1.26x
Revenue
$597.97M
Earnings
$35.92M
Fore. Rev. Growth
20.26%
Fore. Earn. Growth
66.86%
Market Cap
$3.12B
Next Earnings
N/A
Next Dividend
N/A
Fundamentals of KNSA
WallStreetZen was designed to help part-time investors do better fundamental analysis quickly.
There are more short-term assets than short-term liabilities on the KNSA balance sheet.
KNSA profit margin has gone up from -2.4% to 6% in the past year.
There are more short-term assets than long-term liabilities on the KNSA balance sheet.
KNSA's operating cash flow of $102.86M allows it to safely service it's debt of $9.72M.
KNSA earnings of $48.62M is not enough to cover its interest payments.
Signs that KNSA is not financially healthy:
Total KNSA debt is higher than 5 years ago, relative to shareholder equity.
Is KNSA stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 6 Equities analysts who monitor KNSA, the consensus analyst rating on Kiniksa Pharmaceuticals International is a Strong Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
Most Recent KNSA Analyst Recommendations
Roger Song, a top 21% analyst from Jefferies maintains KNSA with a strong buy rating and raises their KNSA price target from $45.00 to $54.00, on Jul 29, 2025.
Last year, KNSA earnings were $35.92M. Over the past three year, KNSA's earnings have increased by -91.34% per year. This was slower than the Biotechnology industry average of 10.67%.
Last year, KNSA revenue was $597.97M. During the last four year, KNSA's revenue has increased by 134.43% per year. This was faster than the Biotechnology industry average of 43.74%.
No, Kiniksa Pharmaceuticals International doesn't provide an income stream by paying out dividends.
KNSA Social Trading Data
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your KNSA purchase
You have two main options:
Market order: A market order is an order to buy or sell a stock at the best possible price. Market orders are usually sufficient.
Limit order: A limit order is an order to buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a specific price, use a limit order.
Hit the Open button and eToro will execute the order.
If you need more assistance buying stocks on eToro, click the helpful video below:
How much does it cost to buy one Kiniksa Pharmaceuticals International share?
As of Dec 9, 2025, it costs $41.14 to buy one share of Kiniksa Pharmaceuticals International stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.243 shares of KNSA.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Is now a good time to buy Kiniksa Pharmaceuticals International stock?
According to 6 Wall Street analysts who monitor Kiniksa Pharmaceuticals International, their consensus recommendation is to buy Kiniksa Pharmaceuticals International stock.
What is the best way to buy Kiniksa Pharmaceuticals International stock?
One way to place an order for Kiniksa Pharmaceuticals International stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.